

# ANDREAS KRONBICHLER, M.D., PH.D. (PRIVAT-DOZENT)

## CURRICULUM VITAE

Department of Internal Medicine IV  
Nephrology and Hypertension  
Medical University Innsbruck

20-06-2023

Andreas.kronbichler@i-med.ac.at  
ORCID ID: 0000-0002-2945-2946  
Twitter: akronbichler

## EDUCATION

---

2020	Donau Universität Krems, Austria Health Care Management Course
2020	Priv. Doz. (=highest academic degree), Medizinische Universität Innsbruck, Austria Internal Medicine
2017	Ph.D., Medizinische Universität Innsbruck, Austria Cardiovascular Medicine
2010	Dr. med. univ., Medizinische Universität Innsbruck, Austria Medicine

## BOARD MEMBERSHIPS (selected)

---

Jun 2022 – ongoing	ERA – European Communication Committee (ECC)
Oct 2020 – ongoing	ERA – Immunonephrology Working Group (IWG) – chair elect
Nov 2022 – Nov 2025	Internal Society of Glomerular Diseases

## EMPLOYMENTS

---

06/2023	Consultant (Renal Medicine), Ass Prof. Medical University Innsbruck
2021 – 05/23	Consultant (Renal Medicine) Clinical Senior Research Associate/University Lecturer Honorary Consultant University of Cambridge/Addenbrooke's Hospital, Cambridge, UK
2015 – 2021	Specialty Registrar (2015 – 2017) Consultant (2017-2021) Head of the Glomerulonephritis, Vasculitis, and Lupus Clinic (since 2018) Medizinische Universität Innsbruck, Austria
2014 – 2015	Honorary Research Fellow Supported by an ERA-EDTA long-term fellowship (supervised by Prof. David Jayne) Addenbrooke's Hospital, Cambridge, UK
2011 – 2014	Registrar Medizinische Universität Innsbruck, Austria
2010 – 2011	Registrar Friedrich-Schiller-Universität Jena, Germany

## CLINICAL Trials

---

Selective C-reactive protein apheresis in ST-elevation myocardial infarction (CRP-STEMI trial) – Investigator-initiated trial

ADVOCATE (Principal Site Investigator; N Engl J Med 2021;384:599-609)

---

### FUNDING

---

Jun 2023	Versus Arthritis (Co-Applicant, £383,480) Defining renal pathotypes in ANCA-associated vasculitis to improve treatment stratification
Sep 2022 – Sep 2023	Vifor Pharma (Main Applicant, £122,742) Natural course of kidney function in ANCA-associated vasculitis
Apr 2022 – Apr 2023	Versus Arthritis (Main Applicant, £99,930) Measuring immunocompetence in autoimmune diseases
Jun 2021 – Jan 2023	Land Tirol (Co-Applicant, 315.226,32 Euro) <i>Mobile application for real-time surveillance of endurance athletes</i>
Jan 2021 – Jun 2022	NIH/NIAID 5UM1AI109565-07 (Main Applicant, \$41,000 USD) <i>Immune Tolerance Network, sICP in ANCA-associated vasculitis</i>
Jul 2020 – Mar 2025	Arthritis Research UK (PI, £290,430,64) <i>The significance of Staphylococcus aureus carriage and granulomatosis with polyangiitis: Pathophysiological alterations unraveled</i>

---

### PUBLICATIONS (selected)

---

236 publications in PubMed/MEDLINE (20-Jun-2023)

Geetha D, **Kronbichler A**, ... Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions. Nat Rev Nephrol 2022; 18:724-737.

Trivioli G, ..., **Kronbichler A**, ... Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management. Nat Rev Rheumatol 2022; 18:559-574.

Gamerith G, ..., **Kronbichler A**. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Ann Rheum Dis 2022, doi: 10.1136/ard-2022-222479.

Windpessl M, ..., **Kronbichler A**. COVID-19 vaccines and kidney disease. Nat Rev Nephrol 2021, 17:291-293.

Wagner J, ..., **Kronbichler A**. The composition and functional protein subsystems of the human nasal microbiome in granulomatosis with polyangiitis: a pilot study. Microbiome 2019; 7:137.

**Kronbichler A**, ... Association of pulmonary hemorrhage, positive proteinase 3, and urinary red blood cell casts with venous thromboembolism in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2019; 71:1888-1893.

De Goffau MC, ..., **Kronbichler A**, ..., Parkhill J. Recognizing the reagent microbiome. Nat Microbiol 2018; 3:851-853.

**Kronbichler A**, ... Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2018; 77:1440-1447.

Van Daalen EE, ..., **Kronbichler A**, ..., Rahmattulla C. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis 2017; 76:1064-1069.

---

### PRESENTATIONS (selected)

---

2023	60 <sup>th</sup> ERA, Milan, Italy; <i>Imlifidase in HLA-sensitised patients, CKJ Pearls</i>
2022	ASN Kidney Week <i>ERA Highlights (Kidney Transplantation)</i>
2022	59 <sup>th</sup> ERA, Paris, France <i>Nephro Pearls (Transplantation), Co-morbidities in ANCA-associated vasculitis</i>
2019	12 <sup>th</sup> ISFA (International Society for Apheresis) Kyoto, Japan <i>Extracorporeal treatment measures in immune-complex small-vessel vasculitides</i>
2019	EUVAS Course (European Vasculitis Society), Cambridge, UK <i>Co-morbidities in ANCA-associated vasculitis</i>
2018	5 <sup>th</sup> Annual F.E.N. Quebec, Canada <i>Rituximab and primary glomerular diseases: Where are we going now?</i>

---

#### **REVIEWER (selected)**

---

Medicine	The New England Journal of Medicine The Lancet Annals of Internal Medicine
Nephrology	Journal of the American Society of Nephrology Kidney International Clinical Journal of the American Society of Nephrology American Journal of Kidney Diseases Nephrology Dialysis Transplantation
Rheumatology	Annals of the Rheumatic Diseases Arthritis Rheumatology Rheumatology
National societies	French Ministry of Health Italian Ministry for Education University and Research Vasculitis UK Austrian National Bank The Icelandic Research Fund

---

#### **MEMBERSHIPS (selected)**

---

German Society of Nephrology (DGfN)  
Austrian Society of Nephrology (ÖGN, board member)  
European Renal Association (ERA)  
Austrian Society of Rheumatology (ÖGR, board member)  
European Vasculitis Society (EUVAS)

**Innsbruck, 20<sup>th</sup> June 2023**



**Ass Prof. Dr. Andreas Kronbichler PhD**